Approval · Notice of Compliance 13875 · 2012
SILDENAFIL: Notice of Compliance 13875
Issued November 22, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13875
- Date
- November 22, 2012
- Company
- Pharmascience Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Admin
- Reason
- Product name change
- Therapeutic class
- Cgmp-specific phosphodiesterase type 5 inhibitor; treatment of erectile dysfunction
- Canadian reference product
- VIAGRA (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SILDENAFIL | 02317559 | Marketed |
| SILDENAFIL | 02317575 | Marketed |
| SILDENAFIL | 02317583 | Marketed |
Medicinal ingredients
- SILDENAFIL CITRATE 25 MG per TAB
- SILDENAFIL CITRATE 50 MG per TAB
- SILDENAFIL CITRATE 100 MG per TAB